ARTICLE | Emerging Company Profile
Looking beyond VEGF
How SemaThera targets vascular pathologies in the retina where anti-VEGF fails
January 12, 2017 8:05 PM UTC
SemaThera Inc. launched this week to develop a recombinant SEMA3A trap to treat vascular pathologies in the large fraction of diabetic macular edema (DME) patients who don’t respond to marketed anti-VEGF therapies.
Semaphorins are a family of secreted and transmembrane proteins that bind a heterocomplex of a plexin protein, a neuropilin, and a cell adhesion molecule. ...
BCIQ Target Profiles